A global supplier of new-energy and semiconductor materials, with net profit growing for eight consecutive years and a 115% surge in performance.

Currently, the hottest investment sectors on China’s A-share market are undoubtedly semiconductors and new energy. In 2021, within less than seven months, the semiconductor sector achieved an average gain of 41.13%, ranking first among all A-share sectors by growth. Among them, Mingwei Electronics—the sector’s leading stock—soared over fivefold. Meanwhile, the lithium-battery segment within the new-energy sector posted an average gain of 32% in just over two months, ranking third among A-share concept sectors by growth. It is remarkable how red-hot both the semiconductor and new-energy sectors were in 2021. So what might be the future prospects of a company operating simultaneously in both arenas? There exists such a company listed on China’s A-share market whose core business is supplying raw materials to global new-energy and semiconductor enterprises. Riding the tailwinds of these two booming sectors, the company has delivered eight consecutive years of net profit growth—and in Q1 2021 alone, its performance surged by 115%. To fully understand this enterprise, the Financial Report Translator conducted an in-depth review of its 2020 annual report and personally contacted the company’s Secretary to the Board for firsthand insights. Through this investigation, the translator aimed to clarify three key questions: First, what exactly does this company do? Second, what factors drove its substantial performance growth? Third, can the company sustain growth in 2021? The translator’s articles do not constitute stock recommendations; they only share research logic. If anything remains unclear, readers are welcome to leave comments—the translator will respond. A company delivering strong performance is like a thoroughbred horse endowed with extraordinary potential. Its stock price appreciation, meanwhile, is akin to that horse being discovered by a discerning connoisseur—drawing attention and enthusiasm from investors and institutions alike. Thus, the translator offers only the thoroughbred—and its user manual. What kind of semiconductor enterprise is this? The company’s Secretary to the Board is a man in his thirties, speaking with warmth and courtesy. Translator: Hello, I’m a shareholder and would like to learn more about your company. Secretary: Hello—please go ahead. Translator: Could you tell me what businesses your company engages in? Secretary: Our main products include semiconductor materials, semiconductor devices, and new-energy materials—covering manufacturing and sales. New-energy materials account for as much as 88% of our revenue, while semiconductor materials represent only 7%. Both are core businesses. The translator believes that, as the semiconductor boom continues, the proportion of semiconductor-materials revenue will gradually rise. Translator: What are the primary applications of your products? Secretary: Our products serve diverse industries—including integrated circuits, photovoltaic power generation, wind power generation, new-energy vehicles, rail transit, aviation, aerospace, and industrial control. This semiconductor enterprise’s product portfolio aligns perfectly with China’s two most pivotal development trends—illustrating precisely the ancient wisdom: “Even superior intelligence is no match for favorable timing; even the finest farming tool cannot replace the right season.” Translator: What raw materials go into your photovoltaic products? Secretary: Our photovoltaic offerings mainly comprise solar silicon wafers and solar cells, plus raw materials supplied to utility-scale and distributed photovoltaic power plants. Distributed photovoltaic power plants are a recently trending concept.

Top Five Healthcare M&A Events of 2024

12. Siemens Healthineers acquired Novartis’ Advanced Accelerator Applications (AAA) to expand its molecular imaging capabilities. This transaction added 13 European production sites to Siemens’ PETNET Solutions network, significantly strengthening its original equipment manufacturer (OEM) capacity for producing and delivering PET radiopharmaceuticals. The newly integrated workforce of approximately 420 employees will operate under Siemens Healthineers as Advanced Accelerator Applications. According to Siemens, the PET diagnostics market served by this acquisition—driven by tracer innovations in oncology, neurology, and cardiology—is valued at €500 million annually and is projected to triple by 2033. PETNET Solutions is the world’s leading producer and distributor of PET radiopharmaceuticals, supplying nearly 1.6 million doses annually to over 2,800 imaging centers globally. 4. Duke Street Acquires AGITO Medical from Philips In July, European private equity firm Duke Street acquired AGITO Medical—a Denmark-based provider of mobile imaging equipment leasing and refurbished imaging systems—from Philips. Founded in 2004, AGITO supplies flexible, customized mobile imaging leasing solutions and refurbished imaging equipment and spare parts to healthcare providers. It serves hospitals and clinics with turnkey mobile imaging services—including CT, MR, and ECG suites—with or without staffing support. James Almond, Duke Street’s Executive Partner, described the deal as a “classic” private equity transaction: spinning off an excellent healthcare product and team from a global corporate giant—and creating value for all stakeholders through targeted investment. The European medical imaging leasing market is currently valued at approximately €500 million and is expected to grow 6–7% annually over the coming years. 5. Avante Health Solutions Files for Chapter 11 Bankruptcy and Agrees to Sale In October, Avante Health Solutions and its affiliated entities filed for Chapter 11 bankruptcy protection in the U.S. District Court for the District of Delaware on October 8, seeking court approval for a sale to private equity firm Staple Street Capital. The company reported assets valued between $50 million and $100 million, and liabilities between $100 million and $500 million—including among its 30 largest unsecured creditors Philips Medical Systems. Avante’s CEO and President Jim Leitl stated: “Facing persistent litigation, our team has worked diligently to strengthen our financial foundation. Over the past several years, Avante has incurred losses totaling approximately $20 million.”

Avient Earnings on Deck: Can Materials Firm Sustain Momentum?

Aug 5, 2026

Avient Corp releases second-quarter earnings expected to show strong performance following a first-quarter beat. Investors will focus on margin trends and the company's transition toward sustainable specialty chemicals.